Dompé CEO: Italy's New Financial Plan Is Boosting Competitiveness
This article was originally published in Scrip
While Italian pharmaceutical companies are still facing the challenge of sustainability, a new financial plan from the government to promote growth in the country that has been introduced over the past couple of years means Dompé's CEO Eugenio Aringhieri is feeling positive about the future of the pharma industry in his country.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.